These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
441 related items for PubMed ID: 17375030
1. Once-daily mesalamine (Lialda) for ulcerative colitis. Med Lett Drugs Ther; 2007 Mar 26; 49(1257):25-6. PubMed ID: 17375030 [No Abstract] [Full Text] [Related]
2. Encapsulated mesalamine granules (Apriso) for ulcerative colitis. Med Lett Drugs Ther; 2009 May 18; 51(1312):38-9. PubMed ID: 19448588 [Abstract] [Full Text] [Related]
3. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H. Clin Gastroenterol Hepatol; 2009 Jul 18; 7(7):762-9. PubMed ID: 19375519 [Abstract] [Full Text] [Related]
4. Once-daily mesalamine granules for ulcerative colitis. Lawlor G, Ahmed A, Moss AC. Expert Rev Clin Immunol; 2010 Jul 18; 6(4):521-6. PubMed ID: 20594123 [Abstract] [Full Text] [Related]
6. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ. Clin Gastroenterol Hepatol; 2007 Jan 18; 5(1):95-102. PubMed ID: 17234558 [Abstract] [Full Text] [Related]
7. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials. Zhu Y, Tang RK, Zhao P, Zhu SS, Li YG, Li JB. Eur J Gastroenterol Hepatol; 2012 May 18; 24(5):487-94. PubMed ID: 22465970 [Abstract] [Full Text] [Related]
9. Ulcerative colitis treatment for children and teens. FDA Consum; 2007 Feb 18; 41(2):5. PubMed ID: 17582854 [No Abstract] [Full Text] [Related]
10. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Sandborn WJ. Rev Gastroenterol Disord; 2006 Feb 18; 6(2):97-105. PubMed ID: 16699478 [Abstract] [Full Text] [Related]
11. Mesalamine (5-aminosalicylic acid) therapy well tolerated in a patient with aspirin hypersensitivity and ulcerative colitis. Murphy SJ, Mayer L, Abreu MT. J Clin Gastroenterol; 2011 Jan 18; 45(1):83-4. PubMed ID: 20535023 [No Abstract] [Full Text] [Related]
12. Mesalamine with MMX technology for the treatment of ulcerative colitis. Schreiber S, Kamm MA, Lichtenstein GR. Expert Rev Gastroenterol Hepatol; 2008 Jun 18; 2(3):299-314. PubMed ID: 19072380 [Abstract] [Full Text] [Related]
13. Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease. Herfarth H, Tjaden C, Lukas M, Obermeier F, Dilger K, Müller R, Schölmerich J, Z T-1 Study Group. Gut; 2006 Oct 18; 55(10):1525-6. PubMed ID: 16966711 [No Abstract] [Full Text] [Related]
14. Accidentally ASCENDing into comparative effective research for inflammatory bowel disease. Siegel CA. Gastroenterology; 2009 Dec 18; 137(6):1880-2. PubMed ID: 19879213 [No Abstract] [Full Text] [Related]
15. [Ulcerative colitis. Acute episode]. Reissmann A, Bischoff SC, Fleig W. Z Gastroenterol; 2004 Sep 18; 42(9):994-8. PubMed ID: 15455271 [No Abstract] [Full Text] [Related]
16. [Mesalazine granules instead of tablets. New ulcerative colitis therapy confirmed also in general practice routine]. MMW Fortschr Med; 2004 Jun 10; 146(24):53. PubMed ID: 15366501 [No Abstract] [Full Text] [Related]
17. [Interstitial nephritis associated with mesalazine therapy]. Vuotila M, Ikäheimo R, Pietiläinen T. Duodecim; 2003 Jun 10; 119(20):1978-82. PubMed ID: 14640003 [No Abstract] [Full Text] [Related]
18. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE. Aliment Pharmacol Ther; 2008 Jun 01; 27(11):1094-102. PubMed ID: 18363894 [Abstract] [Full Text] [Related]